Broadening the infection prevention and control network globally; 2017 Geneva IPC-think tank (part 3).
Anti-Bacterial Agents
/ pharmacology
Antimicrobial Stewardship
Biomedical Research
Centers for Disease Control and Prevention, U.S.
Cross Infection
/ microbiology
Drug Resistance, Multiple, Bacterial
Global Health
Group Processes
Hand Hygiene
Humans
Infection Control
/ methods
Intersectoral Collaboration
Public Health
Switzerland
United States
World Health Organization
CDC
Change
Collaboration
ECDC
Infection prevention and control
Institutional
International
National
Networks
WHO
Journal
Antimicrobial resistance and infection control
ISSN: 2047-2994
Titre abrégé: Antimicrob Resist Infect Control
Pays: England
ID NLM: 101585411
Informations de publication
Date de publication:
2019
2019
Historique:
received:
18
02
2019
accepted:
23
04
2019
entrez:
7
6
2019
pubmed:
7
6
2019
medline:
28
5
2020
Statut:
epublish
Résumé
Healthcare-associated infection (HAI) is a major challenge for patient safety worldwide, and is further complicated by antimicrobial resistance (AMR) due to excessive antimicrobial use in both humans and animals. Existing infection prevention and control (IPC) networks must be strengthened and adapted to better address the global challenges presented by emerging AMR. In June 2017, 42 international experts convened in Geneva, Switzerland, to discuss two key areas for strengthening the global IPC network: 1) broadening collaboration in IPC; and 2) how to bring the fields IPC and AMR control together. The US Centers for Disease Prevention and Control, the European Centre for Disease Prevention and Control, and the World Health Organization (WHO) convened together with international experts to discuss collaboration and networks, demonstrating the participating organizations' commitment to close collaboration in IPC. The challenge of emerging AMR can only be addressed by strengthening this collaboration across international organisations and between public health and academia. The WHO The working group determined that international organisations should take the lead in creating new networks, which will in turn attract academia and other stakeholders to join. At the same time, they should invest in bringing existing IPC and AMR networks under one umbrella. Transmission of multidrug-resistant microorganisms in hospitals and in the community threatens the success of antimicrobial stewardship programmes, and thus, research and development in IPC should be addressed as an enhanced global priority.
Sections du résumé
Background
Healthcare-associated infection (HAI) is a major challenge for patient safety worldwide, and is further complicated by antimicrobial resistance (AMR) due to excessive antimicrobial use in both humans and animals. Existing infection prevention and control (IPC) networks must be strengthened and adapted to better address the global challenges presented by emerging AMR.
Methods
In June 2017, 42 international experts convened in Geneva, Switzerland, to discuss two key areas for strengthening the global IPC network: 1) broadening collaboration in IPC; and 2) how to bring the fields IPC and AMR control together.
Results
The US Centers for Disease Prevention and Control, the European Centre for Disease Prevention and Control, and the World Health Organization (WHO) convened together with international experts to discuss collaboration and networks, demonstrating the participating organizations' commitment to close collaboration in IPC. The challenge of emerging AMR can only be addressed by strengthening this collaboration across international organisations and between public health and academia. The WHO
Conclusions
The working group determined that international organisations should take the lead in creating new networks, which will in turn attract academia and other stakeholders to join. At the same time, they should invest in bringing existing IPC and AMR networks under one umbrella. Transmission of multidrug-resistant microorganisms in hospitals and in the community threatens the success of antimicrobial stewardship programmes, and thus, research and development in IPC should be addressed as an enhanced global priority.
Identifiants
pubmed: 31168366
doi: 10.1186/s13756-019-0528-0
pii: 528
pmc: PMC6509854
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
74Investigateurs
Mohamed Abbas
(M)
Raheelah Ahmad
(R)
Benedetta Allegranzi
(B)
Antoine Andremont
(A)
Mike Bell
(M)
Michael Borg
(M)
Denise Cardo
(D)
Yehuda Carmeli
(Y)
Enrique Castro-Sanchez
(E)
John Conly
(J)
Philippe Eggimann
(P)
Petra Gastmeier
(P)
M Lindsay Grayson
(ML)
Stephan Harbarth
(S)
Marcela Hernandez
(M)
Loreen Herwaldt
(L)
Alison Holmes
(A)
John A Jernigan
(JA)
Claire Kilpatrick
(C)
Amy Kolwaite
(A)
Karl-Heinz Krause
(KH)
Elaine Larson
(E)
Sarah Masson-Roy
(S)
Shaheen Mehtar
(S)
Marc Mendelson
(M)
Ling Moi Lin
(LM)
Andreea Moldovan
(A)
Dominique Monnet
(D)
Babacar Ndoye
(B)
Peter Nthumba
(P)
Folasade Ogunsola
(F)
Ben Park
(B)
Eli Perencevich
(E)
Didier Pittet
(D)
Matthew Samore
(M)
Wing Hong Seto
(WH)
Arjun Srinivasan
(A)
Julie Storr
(J)
Evelina Tacconelli
(E)
Carolyn Tarrant
(C)
Sara Tomczyk
(S)
Maha Talaat
(M)
Maria Virginia Villegas
(MV)
Andreas Voss
(A)
Tim Walsh
(T)
Andreas Widmer
(A)
Walter Zingg
(W)
Déclaration de conflit d'intérêts
Not applicable.Not applicable.The authors declare that they have no competing interests.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Références
Lancet Glob Health. 2017 Dec;5(12):e1178-e1180
pubmed: 29132606